Testing the evolution process of prostate-specific antigen in early stage prostate cancer: What is the proper underlying model?

Statistics in Medicine

Volumn 30, Issue 25, 2011, Pages 3038-3049

  Prisman, Eliezer Z ^a   Gafni, Amiram ^b   Finelli, Antonio ^c  

^a YORK UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active surveillance; Geometric Brownian Motion; Prostate cancer; Stochastic evolution of PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; FACTUAL DATABASE; HYPOTHESIS; IMMUNOASSAY; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; MEDICAL DECISION MAKING; PREDICTION; PROCESS OPTIMIZATION; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; STOCHASTIC MODEL; SYSTEMATIC ERROR; VALIDATION PROCESS;

DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DECISION MAKING; EARLY DETECTION OF CANCER; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; ONTARIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 80054758433     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4329     Document Type: Article

References (22)

1. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening:1986-2005. Journal of the National Cancer Institute 2009; 101(19):1325-1329. DOI: 10.1093/jnci/djp278.
2. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. Journal of Clinical Oncology 2010; 28(1): 126-131. DOI:10.1200/JCO.2009.24.2180.
3. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DEJ, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112(8):1650-1659. DOI: 10.1002/cncr.23373.
4. Svatek RS, Shulman M, Choudhary PK, Benaim E.Critical analysis of prostate-specific antigen doubling time calculation methodology.Cancer 2006; 106(5):1047-1053. DOI: 10.1002/cncr.21696.
5. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Ballentine Carter H, Walsh PC. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. Journal of Clinical Oncology 2010; 28(17):2810-2816. DOI: 10.1200/JCO.2009.25.731.
6. Metcalfe C, Tilling K, Davis M, Lane JA, Martin RM, Kynaston H, Powell P, Neal DE, Hamdy F, Donovan JL. Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. British Journal of Cancer 2009; 101:390-394. DOI: 10.1038/sj.bjc.6605181.
7. Prisman EZ, Gafni A, Finelli T. Risk management and active surveillance: the case of early stage prostate cancer. Journal of Theoretical Biology 2011; 284: 61-70.
8. Dayananda PW, Taylor JMG, Whiting DG. Prostate cancer: progression of prostate-specific antigen after external beam irradiation. Mathematical Biosciences 2003; 182:127-134.
9. Campbell JY, Lo AW, MacKinlay AC. The Econometrics of Financial Markets. Princeton University Press: Princeton NJ, 1997.
10. Sarkar RR, Banerjee S. Cancer self remission and tumor stability-a stochastic approach. Mathematical Biosciences 2005; 196:65-81.
11. Dayananda PWA, Kemper JT, Shvartsman MM. A stochastic model for prostate-specific antigen levels. Mathematical Biosciences 2004; 190:113-126.
12. Bělík P, Dayananda PWA, Kemper JT, Shvartsman MM. A stochastic model for PSA levels: behaviour of solutions and population statistics. Journal of Mathematical Biology 2006; 53:437-463.
13. Hirata Y, Bruchovsky N, Aihara K. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. Journal of Theoretical Biology 2010; 264:517-527.
14. Jackson TL. A mathematical model of prostate tumor growth and androgen-independent relapse. Discrete and Continuous Dynamical Systems-Series B 2004; 4(1):187-201.
15. Veestraeten D. An alternative approach to modelling relapse in cancer with an application to adenocarcinoma of the prostate. Mathematical Biosciences 2006; 199:38-54.
16. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. The Journal of Urology 2006; 176(4):1392-1398. DOI: 10.1016/j.juro.2006.06.103.
17. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. The Journal of the American Medical Association 1999; 281(171):1591-1597. DOI: 10.1001/jama.281.17.1591.
18. Davidson J. Stochastic Limit Theory. Oxford University Press: Oxford, 1994.
19. Mood AM. The distribution theory of runs. The Annals of Mathematical Statistics 1940; 11(4):367-392. DOI: 10.1214/aoms/1177731825.
20. Brownlee KA. Statistical Theory and Methodology in Science and Engineering. Wiley: New York, 1965.
21. Swed FS, Eisenhart C. Tables for testing randomness of grouping in a sequence of alternatives. The Annals of Mathematical Statistics 1943; 14(1):66-87. DOI: 10.1214/aoms/1177731494.
22. Lo AW, MacKinlay AC. The size power of the variance ratio test in finite samples: a Monte Carlo investigation. Journal of Econometrics 1989; 40(2):203-238. DOI: 10.1016/0304-4076(89)90083-3.